1
|
Le Tilly O, Gatault P, Baron C, Bejan‐Angoulvant T, Büchler M, Paintaud G, Ternant D. Is CD25 blockade optimal in kidney transplant patients treated with basiliximab? A target‐mediated drug disposition (TMDD) model. Br J Clin Pharmacol 2022; 88:3500-3505. [DOI: 10.1111/bcp.15235] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2021] [Revised: 01/02/2022] [Accepted: 01/09/2022] [Indexed: 11/29/2022] Open
Affiliation(s)
- Olivier Le Tilly
- Université de Tours, EA 4245 Transplantation, Immunology, Inflammation Tours France
- CHRU de Tours Service de Pharmacologie Médicale Tours France
| | - Philippe Gatault
- Université de Tours, EA 4245 Transplantation, Immunology, Inflammation Tours France
- CHRU de Tours, Department of Nephrology and Transplantation Tours France
| | - Christophe Baron
- Université de Tours, EA 4245 Transplantation, Immunology, Inflammation Tours France
- CHRU de Tours, Department of Nephrology and Transplantation Tours France
| | - Theodora Bejan‐Angoulvant
- Université de Tours, EA 4245 Transplantation, Immunology, Inflammation Tours France
- CHRU de Tours Service de Pharmacologie Médicale Tours France
| | - Matthias Büchler
- Université de Tours, EA 4245 Transplantation, Immunology, Inflammation Tours France
- CHRU de Tours, Department of Nephrology and Transplantation Tours France
| | - Gilles Paintaud
- Université de Tours, EA 4245 Transplantation, Immunology, Inflammation Tours France
- CHRU de Tours Service de Pharmacologie Médicale Tours France
| | - David Ternant
- Université de Tours, EA 4245 Transplantation, Immunology, Inflammation Tours France
- CHRU de Tours Service de Pharmacologie Médicale Tours France
| |
Collapse
|